Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Next Previous
Trial Profile

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prexasertib (Primary) ; Samotolisib (Primary) ; Cetuximab; Cisplatin; Filgrastim; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; Pegfilgrastim; Pemetrexed
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Anal cancer; Biliary cancer; Cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Male breast cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms Study JTJF
  • Sponsors Eli Lilly and Company (India) Pvt. Ltd

    • Most Recent Events

    • 24 Sep 2021 According to Results published in the Targeted Oncology, Hematologic toxicity was dose-limiting, therefore, similar to the approach taken in Part A, the protocol was amended to include Cohorts B2 and B3.
    • 24 Sep 2021 The study was amended to include Cohorts A2 and A3 to evaluate different approaches (G-CSF and an alternate schedule of prexasertib to maximize the dose intensity of prexasertib in the combination), according to Results published in the Targeted Oncology
    • 24 Sep 2021 Results published in the Targeted Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top